Reviewing Management Segments and Changing Reportable Segments
First written in FY2017-Q1. 11 of 14 entries say "Restated". Latest entry: FY2024.
10 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「Because our Group consists solely of the Pharmaceuticals segment, segment information has been omitted.」
Reporting and management under a single segment since fiscal 2021 continue. - FY2024-Q3RestatedAnnual report
「Because the Company has a single segment, the relevant information is omitted.」
Reporting under a single Pharmaceuticals segment continues. - FY2021-Q3RestatedAnnual report
「From the first quarter of the fiscal year, our Group has consolidated the reportable segments ("Prescription Pharmaceuticals" and "Healthcare") and changed to a single segment.」
Reporting and management under a single Pharmaceuticals segment, consolidated from the two segments, continue. - FY2021-Q2RestatedAnnual report
「From the first quarter of the fiscal year, our Group has consolidated the reportable segments ("Prescription Pharmaceuticals" and "Healthcare") and changed to a single segment.」
Reporting and management under a single Pharmaceuticals segment, consolidated from the previous two segments, continue. - FY2021-Q1ReframedAnnual report
「From the first quarter of the fiscal year, our Group has consolidated the reportable segments ("Prescription Pharmaceuticals" and "Healthcare") and changed to a single segment.」
The reporting and management segments were changed from the two existing segments, Prescription Pharmaceuticals and Healthcare, to a single Pharmaceuticals segment. - FY2019RestatedAnnual report
「We have two reportable segments, "Prescription Pharmaceuticals" and "Healthcare," classified based on the similarity of their products and services.」
Management and disclosure based on the two businesses as reportable segments continue. - FY2018RestatedAnnual report
「We have two reportable segments, "Prescription Pharmaceuticals" and "Healthcare," classified based on the similarity of their products and services.」
Management and disclosure under the two segments, Prescription Pharmaceuticals and Healthcare, continue. - FY2018-Q3RestatedAnnual report
「In the Healthcare business, because all shares of ドクタープログラム㈱ held by the Company were transferred on 1 April 2017, ドクタープログラム㈱ has been excluded from the scope of consolidation from the first quarter of the fiscal year. Accordingly, skincare has also been excluded from the business activities previously included in the segment.」
The changes to the scope of consolidation and the business activities of the Healthcare business following the transfer of ドクタープログラム continue to be applied. - FY2018-Q2RestatedAnnual report
「In the Healthcare business, because all shares of ドクタープログラム㈱ held by the Company were transferred on 1 April 2017, ドクタープログラム㈱ has been excluded from the scope of consolidation from the first quarter of the fiscal year. Accordingly, skincare has also been excluded from the business activities previously included in the segment.」
The exclusion of skincare from the scope of consolidation and the business activities of the Healthcare business following the transfer of ドクタープログラム continues to be applied. - FY2018-Q1ReframedAnnual report
「In the Healthcare business, because all shares of ドクタープログラム㈱ held by the Company were transferred on 1 April 2017, ドクタープログラム㈱ has been excluded from the scope of consolidation from the first quarter of the fiscal year. Accordingly, skincare has also been excluded from the business activities previously included in the segment.」
Following the transfer of ドクタープログラム, skincare was excluded from the scope of consolidation and the business activities of the Healthcare business. - FY2017RestatedAnnual report
「Under the new medium-term management plan, "HOPE100—Stage 2—," we are reviewing the management segments of our consolidated group. Accordingly, the reportable segments have been changed from the two existing segments, "Pharmaceuticals" and "Healthcare," to "Prescription Pharmaceuticals" and "Healthcare."」
The changes to the management and reporting segments associated with Stage 2 continue to be applied. - FY2017-Q3RestatedAnnual report
「Under the new medium-term management plan, "HOPE100—Stage 2—(Fiscal 2016 to Fiscal 2019)," we are reviewing the management segments of our consolidated group. Accordingly, from the first quarter of the fiscal year, the reportable segments have been changed from the two existing segments, "Pharmaceuticals" and "Healthcare," to "Prescription Pharmaceuticals" and "Healthcare."」
The changes to the management and reporting segments associated with the new medium-term management plan continue to be applied. - FY2017-Q2RestatedAnnual report
「From the first quarter of the fiscal year, the reportable segments have been changed from the two existing segments, "Pharmaceuticals" and "Healthcare," to "Prescription Pharmaceuticals" and "Healthcare."」
The changes to the management and reporting segments associated with the new medium-term management plan continue to be applied. - FY2017-Q1First statedAnnual report
「Under the new medium-term management plan, “HOPE100 – Stage 2 – (FY2016–FY2019),” we are reviewing the management segments of our consolidated group. Accordingly, we have changed the reportable segments from the former two segments, “Pharmaceutical Business” and “Healthcare Business,” to “Prescription Pharmaceutical Business” and “Healthcare Business.”」
In line with the new medium-term management plan, the Pharmaceutical Business was reclassified for management and disclosure purposes as the Prescription Pharmaceutical Business.